who received ganciclovir for a CMV-positive BAL subsequently developed a significantly lower incidence of interstitial pneumonia than non-treated patients. However, In order to compare PCR with rapid virus culture for the early detection of CMV in bronchoalveolar lavage a number of patients developed pneumonia without a previous positive BAL culture. 2 Shell-vial culture is a rapid (BAL) after bone marrow transplantation, 26 asymptomatic patients were routinely evaluated for the presence culture test compared to conventional virus culture, as it provides a result within 24-72 h. However, this technique of CMV on day 35 using these two techniques. Concurrent blood samples were also analyzed in all cases. CMV has a variable degree of sensitivity and is highly dependent on sample collection and preservation. 4, 5 The polymerase was detected synchronously by both culture and PCR in six of 26 (23%) BAL and in five of 26 (19%) blood chain reaction (PCR) is a powerful method which has now been widely used for the diagnosis of CMV, 6 particularly specimens. Among these positive specimens, three BAL and blood samples were positive in the same patients.
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in organ and bone marrow recipients. [7] [8] [9] [10] [11] The objective of the present study was to evaluate the Five (19%) BAL and five (19%) blood samples were culture-negative but PCR-positive. No BAL or blood additional value of CMV detection by PCR in BAL routinely performed on day 35 after bone marrow transplanspecimens were positive by culture alone. When considering matched BAL-blood samples, five were positive tation in asymptomatic patients. in only one fluid, BAL (n = 3) or blood (n = 2) using culture, while seven were positive in only one fluid, BAL Materials and methods (n = 4) or blood (n = 3) using PCR. Overall, six of 26 (23%) patients had culture-negative but PCR-positive
Patients and clinical specimens results. Three of these six patients were positive only in BAL and two of them subsequently received antiviral Twenty-six patients undergoing allogeneic (n = 24) or autotherapy for development of symptoms suggestive of logous (n = 2) bone marrow transplantation at the Institut CMV infection. We suggest that asymptomatic patients Gustave Roussy were evaluated for the presence of CMV with negative-culture but PCR-positive results on day on day 35 after bone marrow transplantation. They had no 35 in BAL should be subsequently closely monitored for evidence of active respiratory disease and no positive blood the presence of CMV.
culture for CMV before day 35. Patient characteristics are Keywords: bone marrow transplantation; CMV; PCR; summarized in Table 1 . BAL was performed on day 35 and bronchoalveolar lavage Table 1 Patient characteristics (n = 26)
is a frequent cause of morbidity and mortality after bone marrow transplantation. blood samples were drawn concomitantly in all cases dur-CMV1 5′ ATCGCCTGGAGACGCCAT 3′ CMV2 5′ CGTCACCAATAGGGGAGT 3′ ing the routine surveillance of bone marrow recipients. One aliquot of BAL fluid and one aliquot of blood were cultured CMV3 5′ CATTGGAACGCGGATTCC 3′ RTA 5′ GAATTCAGTGGATAACCTGCGGCGA 3′ for CMV and a second aliquot of each fluid was processed for PCR analysis. Culture and PCR analyses were perfor-RTT 5′ GGATCCGCATGGCATTACCGTATGT 3′ RS 5′ AGCAGCACCATCGCCATA 3′ med separately and the results of these two techniques were retrospectively compared. The clinical management of patients was based exclusively on the culture results without taking into account the PCR results on day 35 after PCR technique transplantation. Patients who had a positive BAL and/or DNA (10 l) was amplified in a 50 l reaction consisting blood culture on day 35 were treated. All patients were of: 20 pmol of each primer, 10 mm Tris-HCl, 50 mm KCl, subsequently monitored by weekly blood culture until day 1.5 mm MgCl 2 , 200 m dNTP and 2.5 U Taq polymerase 100 and were treated in the case of positive culture. No (Beckman, Fullerton, CA, USA). To control the quality of PCR assay was performed after day 35. This study was DNA and to exclude the presence of inhibitory molecules, approved by the local ethics committee and informed conamplification of a 268 bp fragment of the human ␤ globin sent was obtained from all patients.
gene was carried out for all samples (Gene Amplimer Betaglobin primers; Perkin-Elmer-Cetus, Foster City, CA, CMV culture USA). Amplification was performed in separate tubes for each set of primers. Thirty cycles were performed in a ther-CMV was isolated from BAL or blood by rapid immunomal cycler (Biometra, Trio-Thermoblock, Tampa, FL, peroxidase staining for the major CMV immediate-early USA) with denaturation for 1 min at 94°C, annealing for protein in infected human embryonic fibroblasts using pre-1 min at 55°C and extension for 2 min at 72°C. viously described techniques.
12
Controls included the HCMV-infected and non-infected fibroblastic cell line MRC5 as positive and negative controls, respectively. DNA extraction PCR products (10 l) were run on a 1.5% agarose gel, BAL and EDTA blood samples were centrifuged at 1000 stained with ethidium bromide and visualized under ultrar.p.m. for 10 min. Cell pellets were resuspended in lysis violet light. All samples were also analyzed by dot-blot buffer (0.9 mm NH 4 CO 3 H, 0.13 m NH 4 Cl) to lyse red cells assay as previously reported. 15 Briefly, PCR products (3 l) for 10 min at 4°C, then centrifuged and treated a second were denatured with 0.4 n NaOH and 25 mm EDTA and time with lysis buffer. Cell pellets (10 6 cells) were stored applied to a nylon membrane (Hybond; Amersham, Les at −20°C when not immediately processed. DNA was Ulis, France) by vacuum filtration. Membranes were extracted using a rapid procedure. 13 Briefly, pellets (10 6 hybridized with a 32 P-labeled oligonucleotide probe at cells) were resuspended in solution A (100 mm KCl, 10 55°C for 1 h and washed twice in 2 × SSPE, 0.1% SDS for mm Tris-HCl pH 8, 2.5 mm MgCl 2 ) and in an equal volume 2 min and once at 50°C in 5 × SSPE, 0.1% SDS for 10 of solution B (10 mm Tris-HCl pH 8, 2.5 mm MgCl 2 , 1% min. Autoradiography was performed for 3 h. Nonidet-P40, 1% Tween 20). They were incubated with proteinase K (200 g/ml) for 1 h at 56°C which was then inactivated for 10 min at 94°C. Samples were then suitable for PCR analysis.
Results
Detection of CMV in BAL and blood by PCR Primers and probes
Two sets of primers were used in this study. Primers CMV1 Twenty-six BAL performed on day 35 after bone marrow transplantation in asymptomatic patients were analyzed and CMV2 amplify a 290 bp segment of the major HCMV immediate-early gene.
14 We have previously determined with concomitant blood samples for the presence of CMV by PCR assay. Primers CMV1 and CMV2 and/or primers the sensitivity of the PCR procedure using these primers. We showed that one viral copy per 10 4 cells, ie 10 copies, RTA and RTT were used for PCR. All positive samples using primers CMV1 and CMV2 were also positive using could be detected by dot-blot assay.
15 Primers RTA and RTT amplify a 406 bp fragment of the Us region. 16 The primers RTA and RTT. On the contrary, although most positive RTA-RTT samples were positive using primers sensitivity of the assay with RTA-RTT primers was determined by adding known amounts of a linearized cosmid CMV1 and CMV2 (89%), some positive RTA-RTT samples were negative with CMV1 and CMV2 (11%). A containing the amplified fragment to DNA from 10 4 peripheral blood leukocyte lysates from seronegative subjects.
sample was considered positive for the presence of CMV when it was positive with at least one set of primers. Over-CMV DNA was consistently detected at a concentration of 30 copies per reaction.
all, 11 of 26 (42%) BAL and 10 of 26 (38%) blood samples were CMV positive. Of the matched BAL-blood samples PCR products amplified with primers CMV1-CMV2 and primers RTA-RTT were analyzed by dot-blot assay using analyzed, seven (27%) samples were positive in both BAL and blood whereas four were positive only in BAL and CMV3 and RS probes, respectively. The sequences of the primers and probes are given below: three were positive only in blood. the samples positive in only one fluid, BAL samples were more frequently positive than blood samples by culture (3/5) and PCR (4/7). However, these differences were not statistically significant (by the Fisher's exact test).
Table 3
Comparison of PCR with virus culture in blood specimens (n = 26)
Clinical outcome Virus culture
In the retrospective study of culture and PCR results, a patient was considered to be positive for the presence of cultures always remained negative for CMV during the fol-(62%) blood samples were culture and PCR-negative. Howlow-up period, as in the patient with a positive PCR result ever, five (19%) BAL and five (19%) blood samples gave in both fluids. Of the two patients with a PCR-positive different results using culture or PCR as they were cultureresult only in blood, one patient had a subsequent CMVnegative but PCR-positive. No BAL or blood specimens positive culture 10 days later and subsequent cultures were positive by culture alone.
always remained negative in the other patient. The results concerning detection of CMV in matched Twelve (46%) patients had PCR-negative results on day BAL-blood samples by PCR and culture are summarized 35. Ten of them did not have any positive culture during in Table 4 . Of the 26 matched samples, 17 (65%) gave the follow-up period. However, two patients had a positive concordant results using culture and PCR techniques. culture 3 weeks later. Specifically, three of these samples were positive in both None of the 26 patients of the present series developed BAL and blood, two were positive in only one fluid, BAL CMV pneumonia. (n = 1) or blood (n = 1), and 12 were negative in both fluids. Nine matched samples (35%) gave different results using culture or PCR. Three of these samples were cultureDiscussion positive in only one fluid, BAL (n = 2) or blood (n = 1), but PCR-positive in both fluids. In addition, six specimens One of the most severe complications after bone marrow were culture-negative in both fluids but PCR-positive in transplantation is interstitial pneumonia. 1 The presence of one fluid, BAL (n = 3) or blood (n = 2), or both (n = 1).
CMV in BAL fluid by culture on day 35 after marrow transplantation was shown to have clinical implications for the subsequent development of CMV pneumonia. 2 However, in ie 10 to 30 viral copies, is in accordance with that preated from the laboratory area in which DNA extraction was performed and negative controls were included in each viously reported by other authors. 10, 11 We found that all culture-positive samples were PCR-PCR assay.
As CMV is able to persist in the host's tissues, detection positive. However, about 20% of BAL and 20% of blood samples were culture-negative but PCR-positive. Considerof latent CMV DNA cannot be eliminated. However, we previously failed to demonstrate latent CMV in alveolar ing a patient to be positive for CMV infection when at least one fluid, BAL or blood, was positive for CMV, six patients macrophages and blood mononuclear cells from asymptomatic non-immunocompromised CMV-seropositive patients (23%) had culture-negative but PCR-positive results. In one half of these patients, within 2 weeks, culture-positive using PCR. 15 The significance of CMV detection only by PCR without subsequent detection by culture remains results were obtained or, despite culture-negative results, clinical symptoms suggestive of CMV infection appeared, unclear. In these cases, the number of viral DNA copies is probably very low, which could be evaluated by PCR leading to antiviral treatment. PCR is therefore an extremely sensitive procedure compared with rapid culture quantification.
In the present series, antiviral treatment was prescribed as it is positive earlier. Detection of the virus by PCR before viral detection by culture has been previously exclusively on the basis of the culture results in BAL and blood samples performed on day 35 and in subsequent reported in various organ recipients 7, 18 including bone marrow recipients. 9, 19 Moreover, PCR was a rapid procedure blood samples performed weekly. Based upon these treatment criteria, none of the patients developed CMV pneuas it could be completed within 48-72 h, which is similar to the time needed for shell vial culture. monia. Although the additional value of PCR for the preemptive treatment of CMV pneumonia seems limited in the The concomitant analysis of both BAL and blood was more sensitive than analysis of one fluid alone, as some present series, we nevertheless suggest that patients who have culture-negative but PCR-positive results on day 35 samples were culture-positive or PCR-positive in only one fluid. Among the samples positive in only one fluid, BAL in BAL or blood should be subsequently monitored more closely for the detection of CMV. samples were more frequently positive than blood samples by culture (3/5) and PCR (4/7). These data therefore suggest that both BAL and blood analysis should be performed on day 35 after bone marrow transplantation.
